Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $23.12 and traded as high as $23.24. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.07, with a volume of 715,624 shares changing hands.

Wall Street Analyst Weigh In

FMS has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 4th. Six analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Reduce” and a consensus target price of $23.57.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.9%

The company’s 50 day moving average price is $23.94 and its two-hundred day moving average price is $23.12. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market cap of $12.39 billion, a PE ratio of 11.95, a PEG ratio of 4.29 and a beta of 0.77.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. The firm had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Brooklyn Investment Group increased its stake in Fresenius Medical Care AG & Co. KGaA by 5.4% during the fourth quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock worth $212,000 after acquiring an additional 450 shares during the last quarter. Advisors Preferred LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 6.1% during the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock valued at $231,000 after purchasing an additional 589 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after purchasing an additional 699 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 4.0% in the 4th quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock valued at $447,000 after purchasing an additional 726 shares during the last quarter. Finally, Arax Advisory Partners boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.